See other companies on Welcome to the Jungle
Element Biosciences
Genetic analysis tools
- 201-500 employees
- B2B
- Enterprise
- Deep Tech
- Biology
- Science
- Sorrento Mesa, San Diego, CA
Jump to section
Company mission
To empower the scientific community with more freedom and flexibility to accelerate our collective impact on humanity.
Our take
Element Bioscience specializes in advanced DNA sequencing and multi-omics technology. Its products offer powerful tools for researchers by combining various biological analyses into a single platform. Allowing scientists to examine DNA, RNA, proteins and other cellular components more efficiently and affordably.
The company aims to democratize access to these cutting-edge genomic tools, making high-quality, flexible and cost-effective solutions available to a broader range of researchers. By improving the accessibility and functionality of their technology, Element is accelerating scientific discoveries and enabling breakthroughs in understanding biological systems.
In an exciting development, the company recently secured substantial funding. This influx of capital will support the commercialization of its existing products and the development of new technologies. It will also help it to expand its global customer base and continue driving innovation.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- 100% company-paid medical, dental, and vision coverage
- Premier mental health care
- Flexible spending accounts & health savings accounts
- $10,000 fertility benefit
- Company-paid Life and AD&D insurance
- Company-paid Short and Long-term disability coverage
- 401(k) with immediately vested 4% company match
- Stock option grants for all full-time regular employees
- Unlimited 1:1 access to Certified Financial Planners
- Paid flexible time off for full-time exempt and non-exempt employees
- Pet Insurance
- Tuition reimbursement
- Free access to 3 local Alexandria EXOS gyms
- Identity theft protection
- Access to discounted tickets, merchandise, and tips
Funding (last 2 of 5 rounds)
Jul 2024
$277m
SERIES D
Jun 2021
$276m
SERIES C
Total funding: $678m
This company has top investors
Leadership
Molly He
(CEO)Has more than 20 years of experience in technology innovation and management in the biotechnology and health industries. Previously a Senior Director of Scientific Research at Illumina, where they won the Innovation Award twice.
Michael Previte
(CTO)Previously an Associate Principal Scientist at Illumina. While there, they pioneered innovations in advanced sequencing technology for both single-molecular and ensemble-based methods.
Matthew Kellinger
(VP of Biochemistry)Earned their PhD in Biochemistry at the University of Texas at Austin. They previously worked as a Staff Scientist at Illumina where they focused on protein engineering to support and develop the future of genome sequencing.